China NT Pharma : VOLUNTARY ANNOUNCEMENT NT BIOPHARMA OBTAINED NEW GMP CERTIFICATION FROM CFDA PRODUCTION AND SALES OF NATIONAL CLASS 1.1 NEW DRUG “XI DI KE” WILL OFFICIALLY COMMENCE

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 01011) VOLUNTARY ANNOUNCEMENT NT BIOPHARMA OBTAINED NEW GMP CERTIFICATION FROM CFDA PRODUCTION AND SALES OF NATIONAL CLASS 1.1 NEW DRUG "XI DI KE"WILL OFFICIALLY COMMENCE

China NT Pharma Group Company Limited (the "Company") and its subsidiaries (collectively, the "Group") are pleased to announce that Jiangsu NT Biopharma Company Limited（ 泰凌生物製藥江蘇有限公司）("NT Biopharma"), a subsidiary of the Company, has successfully obtained the new Good Manufacturing Practices (the "GMP") certification from China Food and Drug Administration ("CFDA"). It is estimated that the production line can commence production of "Xi Di Ke" (uroacitides injection 尿多酸肽注射液）, the national class 1.1 new drug owned by the Group, in March and the sales of "Xi Di Ke" to hospitals will officially commence in April this year.

NT Biopharma, a high-tech biopharmaceutical enterprise with its plants located in the China Medical City in Taizhou, China, covering an area of 100 mu, is the Group's production base for bio-chemical drugs and primarily engages in the production of "Xi Di Ke", a national class

1.1 new anticancer drug with global exclusive intellectual property rights and relevant patents and has obtained approval from CFDA to be launched in the market for the treatment of non- small cell lung cancer and breast cancer. "Myelodysplastic Syndrome (MDS)", a newly added indication, is in phase II and III clinical research process and has been approved by CFDA to enter the green channel for fast approval of innovative drugs. The innovation results are expected to enter the market as soon as possible.

The Group believes that the official commencement of production and sales of "Xi Di Ke" will enlarge the market share of the Group's products in the tumour therapeutic areas and bring strong support to its business and continuous contribution to the growth in its results.

By order of the Board

China NT Pharma Group Company Limited Ng Tit

Chairman

Hong Kong, 3 March 2017

As at the date of this announcement, the executive Directors of the Company are Mr. Ng Tit, Ms. Chin Yu and Mr. Wu Weizhong; the non-executive Directors of the Company are Dr. Qian Wei and Mr. Ge Jianqiu; and the independent non-executive Directors of the Company are Mr. Yue Nien Martin Tang, Mr. Patrick Sun and Dr. Lap-Chee Tsui.